EP Vantage Releases New Half Year Reviews for the Pharma and Medtech Industries
London, Boston, Tokyo - 20 August 2014 - An M&A frenzy that accounted for nearly $90 billion of equity set the pace for the first half of 2014 in the pharma and biotech sectors, but a slowdown in IPOs and six months of volatile market activity could tarnish the year’s shimmering start. Meanwhile, skies appear to have brightened for the medtech sector as improvements, largely fueled by multibillion-dollar deals, occurred across the board.
Pharma 2014 Half-Year Review Highlights
“It’s hard to predict which direction the second half of the year will go and whether controversies over drug pricing and M&A migration overseas mean a rocky road ahead,” said Jonathan Gardner, the report’s author.
“Though some investors have questioned the sustainability of the biotech bull market, we’re able to find a small amount of comfort knowing that at least for now, the NASDAQ index stands at more than two and a half times its previous peak in 2000.”
The full version of the Pharma 2014 Half -Year Review can be at www.evaluategroup.com/PharmaHalfYearReview2014
Medtech 2014 Half-Year Review Highlights
“The most important turnaround for the medtech sector comes in the form of mega-mergers and acquisitions,” said Elizabeth Cairns, author of the report. “Whether this is the beginning of a recovery or the only way companies can seek growth in an industry that is still facing a lot of pricing pushback from payers and patients is not yet clear.”
The full version of the Medtech 2014 Half-Year Review report can be downloaded at
Notes to Editors
About Evaluate Ltd.
Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Our services include EvaluatePharma, EvaluateClinicalTrials and EvaluateMedTech. Our award-winning editorial team, EP Vantage, leverages our strategic analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity.
For more information please visit www.evaluategroup.com
On Twitter: @evaluatepharma @evaluatemedtech, @epclinicaltrial.
If you reference this source, please follow these guidelines:
Source: EP Vantage Medtech Half-Year Review 2014, Evaluate Ltd., www.evaluate.com
Evaluate is a life science market intelligence firm. EP Vantage is our editorial arm that uses our service intel and analysis to drive their analysis and commentary.
We ask that you not post the PDF rather this link to the report:
Our annual world preview of medtech launches the week of Oct 6th.
Issued for and on behalf of Evaluate by Instinctif Partners.
To contact the Evaluate team at Instinctif Partners, email firstname.lastname@example.org
Melanie Toyne-SewellManaging Partner